News >

Trifluridine/Tipiracil Plus Bevacizumab Improves Survival in Patients With mCRC

Published: Tuesday, Jun 26, 2018

Dr. Eric Van Cutsem

Eric Van Cutsem, MD, PhD

Patients with metastatic colorectal cancer (mCRC) who are not eligible for chemotherapy or surgical resection may have a new first-line treatment option, according to findings presented on June 22, 2018, at the 20th World Conference of Gastrointestinal Cancer. Treatment with trifluridine/tipiracil (Lonsurf) combined with bevacizumab (Avastin) improved progression-free survival (PFS) in thsese patients over comparator capecitabine plus bevacizumab.

Lesniewski-Kmak K, Moiseenko V, Saunders M, et al. Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis. Ann Oncol. 2018;29 (suppl 5; abstr O-022).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication